| Literature DB >> 31795133 |
Qing Zhang1, Jia Liu1, Mengmeng Zhang1, Shujun Wei2, Ruolan Li1, Yongxiang Gao2, Wei Peng1, Chunjie Wu1.
Abstract
Rheumatoid arthritis (RA) is a known chronic autoimmune disease can cause joint deformity and even loss of joint function. Fibroblast-like synoviocytes (FLS), one of the main cell types in synovial tissues of RA patients, are key effector cells in the development of RA and are considered as promising therapeutic targets for treating RA. Herbal medicines are precious resources for finding novel agents for treating various diseases including RA. It is reported that induction of apoptosis in FLS is an important mechanism for the herbal medicines to treat RA. Consequently, this paper reviewed the current available references on pro-apoptotic effects of herbal medicines on FLS and summarized the related possible signal pathways. Taken together, the main related signal pathways are concluded as death receptors mediated apoptotic pathway, mitochondrial dependent apoptotic pathway, NF-κB mediated apoptotic pathways, mitogen-activated protein kinase (MAPK) mediated apoptotic pathway, endoplasmic reticulum stress (ERS) mediated apoptotic pathway, PI3K-Akt mediated apoptotic pathway, and other reported pathways such as janus kinase/signal transducers and activators of transcription (JAK-STAT) signal pathway. Understanding the apoptosis induction pathways in FLS of these herbal medicines will not only help clear molecular mechanisms of herbal medicines for treating RA but also be beneficial for finding novel candidate therapeutic drugs from natural herbal medicines. Thus, we expect the present review will highlight the importance of herbal medicines and its components for treating RA via induction of apoptosis in FLS, and provide some directions for the future development of these mentioned herbal medicines as anti-RA drugs in clinical.Entities:
Keywords: apoptosis; fibroblast-like synoviocytes; herbal medicine; rheumatoid arthritis; signal pathway
Year: 2019 PMID: 31795133 PMCID: PMC6995542 DOI: 10.3390/biom9120795
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Death receptors mediated apoptotic pathway in FLS induced by herbal medicines.
Apoptosis inducting activities of herbal medicine and its active components in fibroblast-like synoviocytes.
| Potential Pathways | Detail Mechanisms | Extracts/Monomers (dose/concentration) | Cells/Tissues | Related Genes/Proteins | Reference |
|---|---|---|---|---|---|
| Death receptors mediated apoptotic pathway | Up-regulating Fas and FasL; Down-regulating Bcl-2 | XFC (1.8 g/kg, p.o.) | Synovia tissues in rats | Fas, FasL, Bcl-2 | [ |
| Up-regulating Fas | ERSM (0.4 mg/mL) | RA-FLS | Fas | [ | |
| Up-regulating Caspase-8, Fas and FasL | FSBT (9.5–38 g/kg, p.o.) | Synovia tissues in rats | Caspase-8, Fas, FasL | [ | |
| Up-regulating Caspase-8 and FLIP | Resveratrol (50–400 μM) | rFLS (CIA) | Caspase-8, FLIP | [ | |
| Increasing Fas mRNA | Propyl gallate (64 μg/mL) | RA-FLS | Fas | [ | |
| Up-regulating Caspase -3, -8, -9, and FasL | Daphnetin (40 μg/mL) | rFLS (CIA) | FasL, TNF, Bid, Bax, Bcl-2, Cyt-C, Caspase-3, -8, and -9 | [ | |
| Mitochondrial apoptotic pathway | Up-regulating Bax and Caspase-3; | SWPD (15–25 mg/mL) | RA-FLS | Bcl-2, Bax, Caspase-3 | [ |
| Down-regulating Bcl-2; Activating Caspase-3; | FSNC (0.33–1.32 g/kg) | rFLS (CIA) | Bcl-2, Caspase-3, Cyt-C | [ | |
| Up-regulating Bax and Caspase-3; | DHJS medicated serum, (0.75, 1.5 and 3 g/kg) | rFLS (AIA) | Bax, Bcl-2, and Caspase-3 | [ | |
| Up-regulating p53, Bax and Caspase-3; | SDP (5–15 mg/mL) | rFLS (AIA) | p53, Bax, Caspase-3, Bcl-2 | [ | |
| Up-regulating p53, Bak, Cyt-C, Bax, Caspase-3, -9; | PHSE (25–100 μg/mL) | MH7A | p53, Bax, Bak, Bcl-2, Bcl-xL, Cyt-C, Caspase-3, -9 | [ | |
| Inhibiting proinflammatory cytokines; Up-regulating Caspase-3, -9 and Bax; | GSZD (0.4–1.6 mg/mL) | MH7A, stimulated by TNF-α (20 ng/mL) | Caspase-3, -9, Bax, Bcl-2 | [ | |
| Up-regulating Bax; Down-regulating Bcl-2; | Scopoletin (250–1000 μM) | rFLS (AIA), stimulated by LPS (5 μg/mL) | MCMP, Caspase-3, Bax, Bcl | [ | |
| Up-regulating Caspase-3 and Bax; Down-regulating Bcl-2; | DMHP (10–250 μM) | rFLS (AIA) | Caspase-3, Bax, Bcl-2 | [ | |
| Increasing Caspase-3, -9, Bax and PARP; | Berberine (5–75 μM) | RA-FLS | Caspase-3, -9, Bax, PARP, Bcl-2, Bcl-xL | [ | |
| Up-regulating Bax and Caspase-3; | TAHP (50, 250 μM) | rFLS (AIA) | Bcl-2, Bax, Caspase-3 | [ | |
| Up-regulating Bax and Cyt-C; Down-regulating Bcl-2; | AGPD (10–30 μM) | RA-FLS | Bax, Bcl-2, Caspase-3, Cyt-C | [ | |
| Increasing Caspase-3 activity; Up-regulating Bax and p53; | Gallic acid (0.1, 1 μM) | RA-FLS | Caspase-3,Bax, p53, Bcl-2 | [ | |
| Increasing Caspase-3, -9, PARP, Fas and Bax; | Celastrol (1, 2, 5 μM) | RA-FLS | Caspase-3, -9, PARP, Fas, Bax, Bcl-2 | [ | |
| Increasing Caspase-3, -9, Cyto C; | Quercetin (100–300 μM) | RA-FLS | Caspase-3, -9, Cyto C, Bcl-2 | [ | |
| Up-regulating Bax; Down-regulating Bcl-2; | Bufalin (10–40 nM) | RA-FLS, stimulated by IL-1β (1 ng/mL) | MCMP, Bax, Bcl-2, PARP, Caspase-3, Cyt-C | [ | |
| Up-regulating Bax, cytosolic Cyto C, Apaf-1, Caspase-3, -9; | Tanshinone IIA (2.5–20 μM) | RA-FLS | Bax, Cyto C, Apaf-1, Caspase-3, -9, Bcl-2 | [ | |
| Up-regulating Caspase-3,-8, -9, Bax, Bid and Cyt-C; | Daphnetin (40 μg/mL) | rFLS (CIA) | FasL, TNF, Cyt-C, Bid, Bax, Bcl-2, Caspase-3, -8, -9 | [ | |
| Decreasing MCMP (Δ | Oridonin (5–40 μM) | RA-FLS, stimulated by IL-1β (1 μg/mL) | MCMP, Caspase-3,-9, PARP, Cyt- C | [ | |
| Down-regulating MCMP (Δ | Resveratrol (50–400 μM) | rFLS (AIA), stimulated by H2O2 (5 μM) | MCMP | [ | |
| Up-regulating Bax and Caspase-3; | Pristimerin (0.75–3 μM) | rFLS (AIA) | Bax, Caspase-3, Bcl-2 | [ | |
| Down-regulating Bcl-2/Bax | Liquirtin (0.345–34.5 μM) | RA-FLS | Bcl-2, Bax | [ | |
| Increasing ROS; | Cryptotanshinone (5 μM) | MH7A cells and RA-FLS cells | Bcl-2, Bad, Caspase-3, PARP | [ | |
| NF-κB mediated apoptotic pathway | Down-regulating Bcl-2, MyD88 and TRAF-6 | Sinomenine (0.5–3.2 mM) | RA-FLS | MyD88, TRAF-6, Bcl-2 | [ |
| Up-regulating Bax and IκBα; Down-regulating Bcl-2, p-IKK and p-IκBα | Scopoletin (250–1000 μM) | rFLS (AIA), stimulated by LPS (5 μg/mL) | Bax, IκBα, Bcl-2, p-IKK, p-IκBα | [ | |
| Inhibiting phosphorylation of NF-κB and IκBα; | Curcumin (12.5–80 μM) | RA-FLS, MH7A, stimulated by IL-1β (10 ng/mL) | NF-κB, IKBα, Caspase-3, -7 | [ | |
| Inhibiting phosphorylation of IKK and IκBα; | Celastrol (0.25–2 μM) | RA-FLS | IKK, IκBα, NF-κBp65 | [ | |
| Inhibiting phosphorylation of NF-κBp65 and IKKβ, IκB and MSK1; | XAN (8.7–34.7 μM) | RA-FLS | NF-κBp65, IKKβ, IκB, MSK1, XIAP, Cyclin D1, GADD45a | [ | |
| Down-regulating NF-κB p65, IKKα and IKKβ | JJD medicated serum | RA-FLS | NF-κBp65, IKKα, IKKβ | [ | |
| Decreasing NF-κB p65, phospho-NF-κB p65 and acetyl-NF-κB p65, as well as pro-inflammatory cytokines | Baicalin (10, 20, 30 μM) | RA-FLS | NF-κB p65 | [ | |
| Inhibiting phosphorylation of NF-κBp65 | PLM (5–20 μM) | RA-FLS, stimulated by TNF-α (10 ng/mL) | NF-κBp65 | [ | |
| Down-regulating p-NF-κBp65 and p-IκB | Kaempferitrin (5–20 μM) | MH7A | NF-κBp65, p-NF-κBp65, IκB, p-IκB, | [ | |
| Increasing ROS, cleaved Caspase-9, Cleaved PARP; Decreasing NF-κB p65 | Hypericin (0.25–4 μM) | MH7A | Caspase-9, PARP, NF-κB p65 | [ | |
| Down-regulating XIAP; Up-regulating Caspase 3; | α-Mangostin (6–14 μg/mL) | RA-FLS, stimulated by TNF-α (10 ng/mL) | XIAP, Caspase 3, p65, IκB, IKK | [ | |
| MAPK mediated apoptotic pathway | Up-regulating JNK, p38; Down-regulating ERK; | Diosgenin (40 μM) | RA-FLS, stimulated by IL-1β (1 ng/mL) | JNK, ERK, p38 | [ |
| Up-regulating JNK, p38α; Down-regulating ERK; | Hecogenin and Tigogenin (10, 40 μM) | RA-FLS | JNK, ERK, p38α, Caspase-3,-8,-9 | [ | |
| Up-regulating JNK, p38α; Down-regulating ERK1/2; | Apigenin (25–100 μM) | MH7A | JNK, ERK, p38, Caspase-3, - 7, PARP-1 | [ | |
| Inhibiting Ras-MAPK signaling | Triptolide (0.28–200 nM) | RA-FLS, stimulated by TNF-α (10 ng/mL) | Ras, p38, ERK, JNK | [ | |
| Up-regulating Bax, ERK, P38 and p21; Down-regulating Bcl-2, JNK | XAN (10, 30 μg/mL) | MH7A, stimulated by TNF-α (10 ng/mL) | Bax, ERK, p38, Bcl-2, JNK | [ | |
| Down-regulating JNK and p-JNK | Brucine (0.125–2 mg/mL) | RA-FLS, stimulated by TNF-α (10 ng/mL) | JNK, p-JNK | [ | |
| Up-regulating p38; Activating Caspase-3, -9 | β-Elemene (10–200 μg/mL) | RA-FLS | p38, Caspase- 3, - 9 | [ | |
| ERS mediated apoptotic pathway | Up-regulating CHOP, GRP94 and GRP78; | Hempseed oil (2.5%) | MH7A | CHOP, PARP | [ |
| Up-regulating ATF4, CHOP and XBPI; | DK-59 (10 μM) | MH7A | ATF4, CHOP, XBPI, Caspase-3, -7, PARP, eIF2α, IRE1α, BiP | [ | |
| Up-regulating ATF4 and CHOP; | EJTE (37.5 μg/mL) | MH7A, stimulated by TNF-α (10 ng/mL) | ATF4, CHOP, Caspase- 7, PARP, IeIF2α | [ | |
| Up-regulating Bax and CHOP; | Resveratrol (50–400 μM) | rFLS (AIA), stimulated by H2O2 (5 μM) | CHOP, Bcl-2 | [ | |
| PI3K/AKT mediated apoptotic pathway | Up-regulating Bax; Down-regulating Bcl-2; | DTYD (100, 200 μg/mL) | RA-FLS | Bax, Bcl-2, PI3K, Akt | [ |
| Up-regulating Bax; | SWXB medicated serum (4.32, 8.64, 17.28 g/kg) | RA-FLS | Bax, Bcl-2, PI3K, Akt | [ | |
| Inhibiting phosphorylation of PI3K and Akt | TSDNR (100 μg/L) | rFLS, stimulated by IL-1β (10 μg/L) | PI3K, Akt | [ | |
| Down-regulating HIF-α, p-PI3K, p-Akt, Bax, Bcl-2 in synovial tissue of CIA rats | HGTZFC (0.315 g/kg) | Synovial tissue of CIA rats | HIF-α, p-PI3K, p-Akt, Bcl-2, Bax | [ | |
| Up-regulating Bax; Down-regulating Bcl-2; | Genistein (50–200 μM) | rFLS (CIA) | Bax, Bcl-2, Akt | [ | |
| Up-regulating lncRNA GAS5; Up-regulating cleaved Caspase-3, -9; | Tanshinone IIA (40 µM) | RA-FLS | lncRNA GAS5, Caspase-3, -9, PI3K, Akt | [ | |
| Decreasing Akt and miR-633 | Anacardic acid (5, 30 and 60 µM) | RA-FLS, stimulated by TNF-α (10 ng/mL) | Akt | [ | |
| Inhibiting the phosphorylation of Akt; | Juglone (30 µM) | RA-FLS | Akt, p21 | [ | |
| Up-regulating cleaved Caspase-3, Bax; | Diosgenin (10, 20, 40 μg/mL) | RA-FLS | Caspase-3, Bax, PI3K, Akt, mTOR | [ | |
| Up-regulating Bax; | Pectolinarin (10, 20 µM) | RA-FLS | Bax, Bcl-2, PI3K, Akt | [ | |
| Other | Down-regulating Jak2 and STAT3; | TAHP (50, 250 μM) | rFLS (AIA) | Jak2, STAT3, p-STAT3 | [ |
| Up-regulating Bax, LC3A, ATR, Chk-1 and ATR; | Celastrol (1–5 µM) | RA-FLS | Bax, LC3A, ATR, Chk-1, γ-H2AX, Bcl-2, FasR, Cyclin-b1, Cdc-25, Cdc-2, Caspase-3, -9, PARP | [ | |
| Inducing pro-apoptosis effects on the RA-FLS | Wogonin (111, 0–200 μM) | RA-FLS | [ | ||
| Up-regulating Bax and Caspase-3; Down-regulating Bcl-2; | Matrine (0.75 mg/mL) | rFLS (CIA) | Bax, Bcl-2, Caspase-3, JAK2, STAT1, -3 | [ | |
| Down-regulating VEGF and MMP-3 | 10-HCPT (1, 10 μg/mL) | RA-FLS | VEGF and MMP-3 | [ | |
| Activating Caspase-3, -7; | Tamaractam; CFM; TFM (0.1, 1 µM) | RA-FLS | Caspase-3, -7 | [ | |
| Inducing growth stagnation of synovial cells at G0/G1 stage | HCTD (6.25–100 µg/mL) | rFLS (CIA) | [ | ||
| Up-regulating Bax and LC3A; | Resveratrol (40–320 µM) | RA-FLS, stimulated by H2O2 (5 μM) | Bax, LC3A, Bcl-2, Atg5, LC3B | [ | |
| Inducing pro-apoptosis effects on the RA-FLS | TGP (5–50 μg/mL) | RA-FLS | [ | ||
| Inhibiting pro-inflammatory cytokines; | GSZD (0.4–1.6 mg/mL) | MH7A, stimulated by TNF-α (20 ng/mL) | SOCS1, JAK2, STAT-3, -5 | [ | |
| Inducing pro-apoptosis effects on the RA-FLS | CINA (1,10 μg/mL) | RA-FLS | [ | ||
| Inducing pro-apoptosis effects on the RA-FLS | Paclitaxel (2,4,8 μM) | RA-FLS | [ |
10-HCPT, 10-Hydroxycamptothecine; AGPD, Andrographolide; AIA, adjuvant-induced arthritis; CFM, cis-n-feruloyl-3-o-methylaids; CIA, collagen-induced arthritis; CINA, cinnamic aldehyde; DHJS medicated serum, Medicated serum of Duhuo Jisheng decoction; DMHP, 7,3′-Dimethoxy Hesperetin; DK-59, (E)-3-(3,5-dimethoxyphenyl)- 1-(1-hydroxynaphthalen-2-yl)prop-2-en-1-one; DTYD, Duanteng Yimu Decoction; EJTE, Eupatorium japonicum Thunb. Extracts; extracts from the roots of Salvia miltiorrhiza (ERSM), extracts from the roots of Salvia miltiorrhiza; FLIP, FLICE inhibitory protein; FSBT, Fengshi Bitong Prescription; FLS, fibroblast-like synoviocytes; FSNC, Fengshining Capsule; GSZD, Guizhi-Shaoyao-Zhimu decoction; HCTD, Huangqi Chongteng Drink; HGTZFC, Heiguteng-Zuifenghuoluo Capsule; JJD, Jinwu Jiangu Decoction; MCMP, Measurement of Mitochondrial Membrane Potentia; rFLS, FLS from rats; RA-FLS, FLS from RA patients; PHSE, Pterocarya Hupehensis Skan extracts; PLM, Piperlongumine; SDP, Polysaccharide from the Saposhnikovia divaricate; SWPD, Seaweed Polysaccharide; SWXB, Shuang-wu-xuan-bi granule; TAHP, 5,7,3’-triacetyl hesperetin; TFM, trans-n-feruloyl-3-O-methyla; TGP, total glucosides of paeonia; TSDNR, Total Saponin of Dioscoreae Nipponicae Rhizoma; XAN, 1,7-dihydroxy-, 4-dimethoxyxanthone; XFC, Xinfeng capsule.
Figure 2Mitochondrial dependent apoptotic pathway in fibroblast-like synoviocytes (FLS) induced by herbal medicines.
Figure 3Mitochondrial dependent apoptotic pathway in FLS induced by herbal medicines.
Figure 4Mitogen-activated protein kinase (MAPK) mediated apoptotic pathway in FLS induced by herbal medicines.
Figure 5Endoplasmic reticulum (ER) mediated apoptotic pathway in FLS induced by herbal medicines.
Figure 6PI3K-Akt mediated apoptotic pathway in FLS induced by herbal medicines.
Monomers for inducing apoptosis in fibroblast-like synoviocytes.
| Classification | Monomers | Apoptotic pathways | References |
|---|---|---|---|
| Alkaloids | Berberine | Mitochondrial dependent apoptosis | [ |
| Sinomenine | NF-κB mediated apoptosis | [ | |
| PLM | NF-κB mediated apoptosis | [ | |
| Brucine | MAPK mediated apoptosis | [ | |
| Matrine | Inhibiting JAK/STAT | [ | |
| 10-HCPT | Down-regulating VEGF and MMP-3 | [ | |
| Tamaractam | Caspase activation induced apoptosis and induction of cell arrest | [ | |
| Flavonoids | DMHP | Mitochondrial dependent apoptosis | [ |
| TAHP | Mitochondrial dependent apoptosis | [ | |
| Quercetin | Mitochondrial dependent apoptosis | [ | |
| Liquiritin | Mitochondrial dependent apoptosis | [ | |
| XAN | NF-κB mediated apoptosis | [ | |
| Baicalin | NF-κB mediated apoptosis | [ | |
| Kaempferitrin | NF-κB mediated apoptosis | [ | |
| α-mangostin | NF-κB Mediated apoptosis | [ | |
| Apigenin | MAPK mediated apoptosis | [ | |
| Genistein | PI3K-Akt mediated apoptosis | [ | |
| Pectolinarin | PI3K-Akt mediated apoptosis | [ | |
| Wogonin | Not mentioned | [ | |
| Steroids | Bufalin | Mitochondrial dependent apoptosis | [ |
| Diosgenin | MAPK mediated apoptosis | [ | |
| Hecogenin | |||
| Tigogenin | |||
| Phenylpropanoids | Daphnetin | Death receptors mediated | [ |
| Scopoletin | Mitochondrial dependent apoptosis | [ | |
| Curcumin | NF-κB mediated apoptosis | [ | |
| CINA | Not mentioned | [ | |
| Terpenoids | AGPD | Mitochondrial dependent apoptosis | [ |
| Oridonin | Mitochondrial dependent apoptosis; | [ | |
| Celastrol | Mitochondrial dependent apoptosis; | [ | |
| Pristimerin | Mitochondrial dependent apoptosis | [ | |
| Triptolide | MAPK mediated apoptosis | [ | |
| β-Elemene | MAPK mediated apoptosis | [ | |
| Paclitaxel | Not mentioned | [ | |
| Quinones | Cryptotanshinone | Mitochondrial dependent apoptosis | [ |
| Hypericin | NF-κB mediated apoptosis | [ | |
| Tanshinone IIA | PI3K-Akt mediated apoptosis | [ | |
| Others | Propyl gallate | Death receptors mediated apoptosis | [ |
| Gallic acid | Mitochondrial dependent apoptosis | [ | |
| Resveratrol | Mitochondrial dependent apoptosis | [ | |
| DK-59 | ERS mediated apoptosis | [ | |
| Anacardic acid | PI3K-Akt mediated apoptosis | [ |
10-HCPT, 10-Hydroxycamptothecine; AGPD, Andrographolide; CFM, cis-n-feruloyl-3-o-methylaids; CINA, Cinnamic aldehyde; DK-59, (E)-3-(3,5-dimethoxyphenyl)- 1-(1-hydroxynaphthalen-2-yl)prop-2- en-1-one; DMHP, 7,3′-Dimethoxy Hesperetin; PLM, Piperlongumine; TAHP, 5,7,3′-triacetyl hesperetin; TFM, trans-n-feruloyl-3-O -methyla; XAN, 1,7-dihydroxy-,4-dimethoxyxanthone.
Figure 7The related monomers for inducing apoptosis in FLS. Resveratrol (1), Propyl gallate (2), Daphnetin (3), Scopoletin (4), 7, 3′-dimethoxy hesperetin (5), Berberine (6), 5,7,3′-triacetyl hesperetin (TAHP, 7), Andrographolide (8), Gallic acid (9), Celastrol (10), Quercetin (11), Bufalin (12), Tanshinone IIA (13), Oridonin (14), Pristimerin (15), Liquiritin (16), Cryptotanshinone (17), Sinomenine (18), Curcumin (19), 1,7-dihydroxy-3,4-dimethoxyxanthone (XAN, 20), Baicalin (21), Piperlongumine (22), Kaempferitrin (23), Hypericin (24), α-mangostin (25), Diosgenin (26), Hecogenin (27), Tigogenin (28), Apigenin (29), β-Elemene (30), Triptolide (31), Brucine (32), (E)-3-(3,5-dimethoxyphenyl)-1-(1-hydroxynaphthalen-2-yl)-prop-2-en-1-one (DK-59, 33), Genistein (34), Anacardic acid (35), Pectolinarin (36), Matrine (37), 10-Hydroxycamptothecine (10-HCPT, 38), Tamaractam (39), Cis-N-feruloyl-3-O-methylaids (40), Trans-N-feruloyl-3-O-methylaids (41), Wogonin (42), Cinnamic aldehyde (CINA, 43), and Paclitaxel (44).
Figure 8The different apoptotic pathways of the natural monomers isolated from herbal medicines. 10-HCPT, 10-Hydroxycamptothecine; AGPD, Andrographolide; CFM, cis-n-feruloyl-3-o-methylaids; CINA, Cinnamic aldehyde; DK-59, (E)-3-(3,5-dimethoxyphenyl)-1-(1-hydroxynaphthalen-2-yl)prop-2-en-1-one; DMHP, 7,3′-Dimethoxy Hesperetin; PLM, Piperlongumine; TAHP, 5,7,3′-triacetyl-hesperetin; TFM, trans-n-feruloyl-3-O-methyla; XAN, 1,7-dihydroxy-,4-dimethoxyxanthone.